Madrid

• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri … Ended
  2023-504036-17-00 5 2020-05-07 Chronic Lymphocytic Leukemia (CLL)
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 5 2020-03-27 Retinopathy of prematurity
• Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended
  2022-501018-78-00 5 2020-03-23 Axial Spondyloarthritis
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Ended
  2023-508956-20-00 5 2020-03-12 Hidradenitis suppurativa
• A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/ … Ended
  2023-503749-76-00 1 2020-03-06 Solid Tumors
• Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) Ended
  2023-509542-35-00 3 2020-03-02 Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD
• A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended
  2023-507389-15-00 4 2020-02-26 Advanced Melanoma
• Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a … Ended
  2023-508826-92-00 3 2020-02-14 Patients with PIK3CA-mutant, HER2-positive locally advanced or metasta
• Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Ended
  2023-509866-39-00 3 2020-02-14 Locally advanced/metastatic breast or non-small cell lung cancer
• An extension study to learn about the long-term safety of fenfluramine hydrochloride for seizures in children and adults with rare seizure d … Ended
  2024-515680-61-00 5 2020-02-07 Dravet syndrome or Lennox-Gastaut syndrome
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 4 2020-01-17 Chronic myelogenous leukemia
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations Ended
  2023-510301-18-00 4 2019-12-05 Advanced solid tumors (other than Urothelial tumors), and FGFR gene al
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 … Ended
  2022-502630-71-00 6 2019-11-20 Attention-deficit/hyperactivity disorder (ADHD)
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Ended
  2023-507883-38-00 5 2019-11-18 Systemic Juvenile Idiopathic Arthritis
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended
  2024-512005-87-00 4 2019-11-07 Lung Cancer
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells … Ended
  2024-511520-13-00 3 2019-11-04 Inherited metabolic disorder of the enzyme pyruvate kinase which affec
• A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generali … Ended
  2023-506688-32-00 5 2019-10-09 Primary Generalized Tonic-Clonic Seizures

Showing 3,409–3,432 of 3,601 trials